Immunotoko

Immunotoko is a Japanese clinical-stage biotechnology company specializing in the development of innovative cancer immunotherapies. The company focuses on oncolytic virus therapy, particularly utilizing modified herpes simplex viruses to target malignant brain tumors like glioblastoma. Founded on research from Chiba University, Immunotoko leverages the body's immune system to eradicate treatment-resistant cancer cells. Their lead program, T-01, involves a third-generation oncolytic HSV-1 vector designed for enhanced safety and efficacy. The company has conducted investigator-initiated clinical trials in Japan, demonstrating a commitment to translating academic breakthroughs into clinical applications. Immunotoko's platform technology aims to provide new therapeutic options for patients with high-grade gliomas and other solid tumors.